CN104922604A - Traditional Chinese medicine composition for treating seasonal allergic conjunctivitis and application of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating seasonal allergic conjunctivitis and application of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN104922604A CN104922604A CN201510397379.9A CN201510397379A CN104922604A CN 104922604 A CN104922604 A CN 104922604A CN 201510397379 A CN201510397379 A CN 201510397379A CN 104922604 A CN104922604 A CN 104922604A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- conjunctivitis
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010010744 Conjunctivitis allergic Diseases 0.000 title claims abstract description 17
- 208000002205 allergic conjunctivitis Diseases 0.000 title claims abstract description 17
- 208000024998 atopic conjunctivitis Diseases 0.000 title claims abstract description 15
- 230000001932 seasonal effect Effects 0.000 title claims abstract description 14
- 241000218176 Corydalis Species 0.000 claims abstract description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 12
- 230000036783 anaphylactic response Effects 0.000 claims description 12
- 208000003455 anaphylaxis Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- -1 after centrifugal Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 240000006891 Artemisia vulgaris Species 0.000 abstract 1
- 244000104272 Bidens pilosa Species 0.000 abstract 1
- 235000010662 Bidens pilosa Nutrition 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 235000010254 Jasminum officinale Nutrition 0.000 abstract 1
- 240000005385 Jasminum sambac Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 230000001741 anti-phlogistic effect Effects 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000002445 nipple Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 201000004484 acute conjunctivitis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 201000005539 vernal conjunctivitis Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015993 Eyelid oedema Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 241000223783 Glaucoma Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine and relates to a traditional Chinese medicine composition and the medical application thereof, in particular to a traditional Chinese medicine composition for treating the seasonal allergic conjunctivitis and the application of the traditional Chinese medicine composition. The traditional Chinese medicine composition for treating the seasonal allergic conjunctivitis comprises 15 parts of radix achyranthis bidentatae, 6 parts of radix paeoniae rubra extractive, 10 parts of honeysuckle, 10 parts of jasmine, 10 parts of rhizoma cimicifugae, 20 parts of mugwort, 20 parts of rhizoma alismatis, 10 parts of corydalis tuber, 5 parts of sticktight, 5 parts of turmeric and 10 parts of poria cocos. The traditional Chinese medicine composition has the very good treating effect on treating the seasonal allergic conjunctivitis and has the obvious clinical popularization value.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of Chinese medicine composition and the application as seasonal allergic conjunctivitis medicine thereof.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, be conjunctival tissue in the effect of the extraneous and body oneself factor general designation of inflammatory reaction that occurs.Because most of conjunctiva directly contacts with the external world, therefore the stimulation of infectious (as antibacterial, virus and chlamydia etc.) and non-infectious factor (wound, chemical substance and physical factor etc.) in surrounding is easily subject to, and the blood vessel of conjunctiva and lymphoid tissue are enriched, the antigen in self and the external world easily makes its sensitization.Seasonal allergic conjunctivitis has another name called hay fever conjunctivitis (hay fever conjunctivitis), and be the modal type of ocular allergies disease, its sensitinogen is mainly the pollen of plant.This sick principal character is seasonal outbreak (usually in spring); Usual eyes morbidity, onset is rapid, shows effect when contacting sensitinogen, and after departing from sensitinogen, symptom is alleviated very soon or disappears.Modal symptom is ophthalmic pruritus, and nearly all patient all can occur, light and heavy degree differs.Also can have foreign body sensation, burn feeling, shed tears, the performance such as photophobia and mucus secretions, exacerbation of symptoms under hot environment.
Seasonal allergic conjunctivitis main physical signs is conjunctival congestion and non-specific palpebral conjunctiva nipple hypertrophy, and be sometimes associated with chemosis or blepharoedema, child Geng Yi occurs.Seldom affect cornea, occasionally have the performance of slight PEK.Many patients have allergic rhinitis and bronchial asthma medical history.
Treatment clinically for seasonal allergic conjunctivitis adopts the merging of eye drop eye drip to take Claritin to treat usually, and achieve good clinical short-term curative effects, but because these Western medicine mostly have potential hepatotoxicity, and action target spot is single, long-term taking can affect the health status of patient.Therefore research and develop the effective medicine of a kind of conjunctivitis to be of great practical significance.
The history of Chinese medicine conjunctivitis is of long standing and well established, and as an importance of modern oculopathy Comprehensive Treatment, more and more receives publicity in recent years.Zhang Yanli use in " Chinese medicine moves back the observation of curative effect of red collyrium to acute conjunctivitis " is moved back red collyrium flushing conjunctival sac treatment acute conjunctivitis and is achieved good clinical therapeutic efficacy.Wu Qingbo " herbal fumigation treatment vernal conjunctivitis in Functional observation " in disclose a kind of Chinese medicine compound (Herba Schizonepetae 10g, art thief 10g, Flos Chrysanthemi Indici 12g,
Periostracum Cicadae 10g, the Fructus Kochiae 109, Fructus Atriplicis Sibiricae 10g, Radix Aconiti Preparata 3g, Herba Asari 3g Herba Siegesbeckiae 15g, Radix Sophorae Flavescentis 10g, Zaocys lO g, Radix Platycodonis 10g, Semen Armeniacae Amarum 10g, Cortex Dictamni 12g, Radix Glycyrrhizae 12), the effect taking afterwards and can have treatment and prevention of recurrence to vernal conjunctivitis first smoked by this medicine.
Summary of the invention
For the deficiency of current conjunctivitis clinical treatment medicine, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of conjunctivitis, and this Chinese medicine composition has good therapeutic effect in treatment inflammatory conjunctivitis, bacterial conjunctivitis, viral conjunctivitis and anaphylaxis conjunctivitis.Chinese medicine composition of the present invention, raw material primarily of following weight portion obtains: Radix Achyranthis Bidentatae 15 parts, Radix Paeoniae Rubra extract 6 parts, Flos Lonicerae 10 parts, Fructus Gardeniae 10 parts, Rhizoma Cimicifugae 10 parts, Radix Artemisia ordosicae 20 parts, Rhizoma Alismatis 20 parts, Rhizoma Corydalis 10 parts, Herba Bidentis Bipinnatae 5 parts, 5 parts, Rhizoma Curcumae Longae, 10 parts, Poria, wherein the preparation method of Radix Paeoniae Rubra extract is: get Radix Paeoniae Rubra dry product grinding and sieving, use the aqueous acetone solution reflux, extract, 2h of 50%, filter, filtering residue uses the aqueous acetone solution reflux, extract, twice of 50% again, merge extractive liquid, after centrifugal, supernatant is evaporated to the extractum of relative density 1.05-1.10, extractum is dried and is pulverized to constant weight, obtain Radix Paeoniae Rubra extract.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, after drying, namely obtain Chinese medical concrete; Pulverized the Radix Paeoniae Rubra extract adding recipe quantity after making dried cream powder, Chinese medicine composition of the present invention can be obtained.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment conjunctivitis medicine.Wherein said conjunctivitis is preferably seasonal allergic conjunctivitis.By the antiinflammatory action investigating Chinese medicine composition xylol induced mice inflammatory model of the present invention, the embodiment of the present invention 4 confirms that Chinese medicine composition provided by the invention can have significant anti-inflammatory efficacy, its antiphlogistic effects is better than hydrocortisone, wherein high dose group and the antiphlogistic effects of middle dosage group have significant difference (P < 0.05) compared with hydrocortisone, this acts on comprehensively when showing traditional Chinese medicine composition for treating inflammatory conjunctivitis of the present invention, has obvious synergism, achieves unforeseeable curative effect of medication.The embodiment of the present invention 5 has investigated the therapeutic effect of Chinese medicine composition of the present invention to anaphylaxis conjunctivitis, find that Chinese medicine composition of the present invention can alleviate anaphylaxis conjunctivitis symptom, its total effective rate for anaphylaxis conjunctivitis is significantly higher than common drug Cetirizine hydrochloride tablet.
In a word, the present invention compared with prior art, have the activity for the treatment of conjunctivitis very well, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as conjunctivitis medicine, drug effect is comprehensive, while dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, conjunctivitis conditions of patients can be made rapidly to take a turn for the better; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good potential applicability in clinical practice.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.In following embodiment, the preparation method of described Radix Paeoniae Rubra extract is: get Radix Paeoniae Rubra dry product grinding and sieving, use the aqueous acetone solution reflux, extract, 2h of 50%, filter, filtering residue uses the aqueous acetone solution reflux, extract, twice of 50% again, and supernatant is evaporated to the extractum of relative density 1.05-1.10 by merge extractive liquid, after centrifugal, extractum is dried and is pulverized to constant weight, obtains Radix Paeoniae Rubra extract.
Part I, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: Radix Achyranthis Bidentatae 15 parts, Radix Paeoniae Rubra extract 6 parts, Flos Lonicerae 10 parts, Fructus Gardeniae 10 parts, Rhizoma Cimicifugae 10 parts, Radix Artemisia ordosicae 20 parts, Rhizoma Alismatis 20 parts, Rhizoma Corydalis 10 parts, Herba Bidentis Bipinnatae 5 parts, 5 parts, Rhizoma Curcumae Longae, 10 parts, Poria.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75% (v/v), leaves standstill 24 hours, gets supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
Embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: Radix Achyranthis Bidentatae 15 parts, Radix Paeoniae Rubra extract 6 parts, Flos Lonicerae 10 parts, Fructus Gardeniae 10 parts, Rhizoma Cimicifugae 10 parts, Radix Artemisia ordosicae 20 parts, Rhizoma Alismatis 20 parts, Rhizoma Corydalis 10 parts, Herba Bidentis Bipinnatae 5 parts, 5 parts, Rhizoma Curcumae Longae, 10 parts, Poria.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80% (v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: Radix Achyranthis Bidentatae 15 parts, Radix Paeoniae Rubra extract 6 parts, Flos Lonicerae 10 parts, Fructus Gardeniae 10 parts, Rhizoma Cimicifugae 10 parts, Radix Artemisia ordosicae 20 parts, Rhizoma Alismatis 20 parts, Rhizoma Corydalis 10 parts, Herba Bidentis Bipinnatae 5 parts, 5 parts, Rhizoma Curcumae Longae, 10 parts, Poria.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
The antiinflammatory action of embodiment 4 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone is synthetic is also naturally occurring glucocorticoid, after hydrocortisone enters cell, activates cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.Hydrocortisone has stronger anti-inflammatory activity, is usually used in the treatment of arthritis, conjunctivitis clinically.
1, experimental technique:
50 KM mices, male and female half and half, body weight 25-30 gram, 5 groups are divided at random, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 50mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in compositions: gavage gives 20mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Compositions low dose group: gavage gives 5mg/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
Experimental result: measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 2.
Table 1 each experimental mice ear method of double differences compares
Compare with model control group,
*p < 0.05; Compare with model control group,
*p < 0.01;
Compare with positive controls,
#p < 0.05; Compare with positive controls,
##p < 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
Embodiment 5 Chinese medicine composition of the present invention is to the therapeutical effect of anaphylaxis conjunctivitis
Anaphylaxis conjunctivitis is a para-immunity disease, and usually have obvious ophthalmic pruritus, conjunctival congestion, papillary hypertrophy and follicle hypertrophy, corneal has no significant effect more, and the longer sings and symptoms of the course of disease is heavier.Treatment anaphylaxis conjunctivitis is based on eye local application, and main purpose is mitigation symptoms and avoids sequela occurs.Antihistaminic, vasoconstrictor, mast cell stabilizers, NSAID (non-steroidal anti-inflammatory drug), glucocorticoid etc. are the common drug of topical therapeutic anaphylaxis conjunctivitis in recent years.
1 clinical data
1) inclusive criteria
Seasonal allergic conjunctivitis except seasonality outbreak and symptom, somatic feature score all relatively low except, other clinical characters are quite similar with perennial allergic conjunctivitis, so both unified to include in.Diagnosis is main with reference to " Chinese ophthalmology " (1) symptom: ophthalmic pruritus, shed tears, burning sensation, foreign body sensation, photophobia and secretions increases (mostly being mucus).(2) sign: conjunctival congestion, edema, palpebral conjunctiva nipple follicle hypertrophy.
2) exclusion standard
With eye patients such as keratitis, xerophthalmia, glaucomas; Within nearly 1 month, execute ophthalmic surgery; Use may other hydryllin of influence research result, mast cell stabilizers and corticosteroid collyrium, nasal mist or systemic drug patient; Intentionally, the patient of the severe primary disease such as brain, liver, kidney and hemopoietic system; Not by regulation medication, the infull person of curative effect or data cannot be judged.
3) physical data
Meet seasonal allergic conjunctivitis 66 example of above-mentioned standard through making a definite diagnosis and perennial allergic conjunctivitis 24 example totally 90 routine.Clients is divided into two groups by the method making a definite diagnosis rear employing district group random: treatment group 45 example, man 19 example, female 26 example; Age 19-66 year (average 36.2 years old).Matched group 45 example, man 21 example, female 24 example; Age 17-65 year (average 35.8 years old).Two groups of physical data are through statistical procedures, and no significant difference (P>0.05), has comparability.
2 Therapeutic Method
For oral administration from intending conjunctivitis mixture.Prescription: Radix Achyranthis Bidentatae 15 grams, Radix Paeoniae Rubra extract 6 grams, Flos Lonicerae 10 grams, Fructus Gardeniae 10 grams, Rhizoma Cimicifugae 10 grams, Radix Artemisia ordosicae 20 grams, Rhizoma Alismatis 20 grams, Rhizoma Corydalis 10 grams, Herba Bidentis Bipinnatae 5 grams, 5 grams, Rhizoma Curcumae Longae, 10 grams, Poria.Be decocted in water for oral dose, every day 1 dose, 2 times/d, successive administration 5 days.Matched group takes Cetirizine hydrochloride tablet (Lunan Beite Pharmaceutical Co., Ltd. produces, 10mg/ sheet, a slice on the one).Within 1 week, carry out checking and following up a case by regular visits to after 3 days, 5 days, 7 days and drug withdrawal after the treatment respectively, record eye subjective symptom and slit lamp examination palpebra inferior, conjunctiva, cornea.
3, therapeutic effect
Curative effect determinate standard: adopt " clinical characters of anaphylaxis conjunctivitis ".Symptom and sign standards of grading evaluation index: ophthalmic pruritus, shed tears, foreign body sensation, eyelid nipple, palpebral follicles, secretions, conjunctival congestion, chemosis.And calculate symptom integral.Computing formula: total mark × 100% before total mark decline index=(before treatment the rear total mark of total mark-treatment)/treatment.Effective: integration reduces >70%; Effective: integration reduces 30%-70%; Invalid: integration reduces <30%.
Table 2 Chinese medicine composition of the present invention is to the therapeutic effect of anaphylaxis conjunctivitis
| Group | N | Effective | Effectively | Invalid | Total effective rate |
| Administration group | 45 | 24 * | 18 * | 3 | 93.3％ * |
| Matched group | 45 | 15 | 9 | 11 | 75.6％ |
Compare with matched group,
*p < 0.05
As can be seen from Table 2, Chinese medicine composition of the present invention is significantly better than cetirizine hydrochloride for the therapeutic effect of anaphylaxis conjunctivitis.
Claims (5)
1. treat the Chinese medicine composition of seasonal allergic conjunctivitis for one kind, it is characterized in that it obtains primarily of the raw material of following weight portion: Radix Achyranthis Bidentatae 15 parts, Radix Paeoniae Rubra extract 6 parts, Flos Lonicerae 10 parts, Fructus Gardeniae 10 parts, Rhizoma Cimicifugae 10 parts, Radix Artemisia ordosicae 20 parts, Rhizoma Alismatis 20 parts, Rhizoma Corydalis 10 parts, Herba Bidentis Bipinnatae 5 parts, 5 parts, Rhizoma Curcumae Longae, 10 parts, Poria, wherein the preparation method of Radix Paeoniae Rubra extract is: get Radix Paeoniae Rubra dry product grinding and sieving, use the aqueous acetone solution reflux, extract, 2h of 50%, filter, filtering residue uses the aqueous acetone solution reflux, extract, twice of 50% again, merge extractive liquid, after centrifugal, supernatant is evaporated to the extractum of relative density 1.05-1.10, extractum is dried and is pulverized to constant weight, obtain Radix Paeoniae Rubra extract.
2. Chinese medicine composition as claimed in claim 1, is characterized in that described Chinese medicine composition is mixture, tablet or capsule.
3. prepare the method for Chinese medicine composition as claimed in claim 1 or 2 for one kind, it is characterized in that it comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, this relative density is testing result at 60 c, adding ethanol to alcohol content is 60-90% (v/v), leaves standstill 24 hours, gets supernatant, reclaim ethanol to concentrated, after drying, namely obtain Chinese medical concrete; Pulverized the Radix Paeoniae Rubra extract adding recipe quantity after making dried cream powder, Chinese medicine composition of the present invention can be obtained.
4. the purposes of Chinese medicine composition as claimed in claim 1 or 2 in preparation treatment conjunctivitis medicine.
5. medicinal usage as claimed in claim 4, is characterized in that described conjunctivitis is anaphylaxis conjunctivitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510397379.9A CN104922604B (en) | 2015-07-04 | 2015-07-04 | A kind of Chinese medicine composition and application thereof for the treatment of seasonal allergic conjunctivitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510397379.9A CN104922604B (en) | 2015-07-04 | 2015-07-04 | A kind of Chinese medicine composition and application thereof for the treatment of seasonal allergic conjunctivitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104922604A true CN104922604A (en) | 2015-09-23 |
| CN104922604B CN104922604B (en) | 2016-04-20 |
Family
ID=54110252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510397379.9A Expired - Fee Related CN104922604B (en) | 2015-07-04 | 2015-07-04 | A kind of Chinese medicine composition and application thereof for the treatment of seasonal allergic conjunctivitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104922604B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075191A (en) * | 2016-07-27 | 2016-11-09 | 刘澍 | A kind of Chinese medicine treating anaphylaxis conjunctivitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083569A (en) * | 2011-11-07 | 2013-05-08 | 李海龙 | Chinese medicament for treating conjunctivitis and preparation method thereof |
| CN103550619A (en) * | 2013-11-14 | 2014-02-05 | 青岛农业大学 | Traditional Chinese medicine preparation for clearing away heat and toxic materials |
| CN104027750A (en) * | 2014-06-27 | 2014-09-10 | 王家玲 | Traditional Chinese medicament for treating conjunctivitis |
-
2015
- 2015-07-04 CN CN201510397379.9A patent/CN104922604B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083569A (en) * | 2011-11-07 | 2013-05-08 | 李海龙 | Chinese medicament for treating conjunctivitis and preparation method thereof |
| CN103550619A (en) * | 2013-11-14 | 2014-02-05 | 青岛农业大学 | Traditional Chinese medicine preparation for clearing away heat and toxic materials |
| CN104027750A (en) * | 2014-06-27 | 2014-09-10 | 王家玲 | Traditional Chinese medicament for treating conjunctivitis |
Non-Patent Citations (5)
| Title |
|---|
| 孟青青，高健生，宋剑涛: "《过敏性结膜炎的治疗研究进展》", 《中国中医眼科杂志》 * |
| 李志勇: "春季结膜炎临床治疗的进展", 《天津中医学院学报》 * |
| 李浩博，高卫萍: "《中医药治疗免疫性结膜炎概况》", 《湖南中医杂志》 * |
| 王科蕾等: "免疫性结膜炎的中医药治疗研究", 《长春中医药大学学报》 * |
| 秦祖杰: "中医药治疗春季卡他性结膜炎近况", 《华夏医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075191A (en) * | 2016-07-27 | 2016-11-09 | 刘澍 | A kind of Chinese medicine treating anaphylaxis conjunctivitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104922604B (en) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836228B (en) | Chinese medicinal composition for treating conjunctivitis and preparation method and application thereof | |
| CN102716394A (en) | Medicine composition for treating skin diseases | |
| CN104922604B (en) | A kind of Chinese medicine composition and application thereof for the treatment of seasonal allergic conjunctivitis | |
| Man | Complementary and alternative medicine for allergic rhinitis | |
| CN103356914B (en) | Decoction for treatment of constipation | |
| CN103830355B (en) | Oleum Nigellae nasal drop and preparation method thereof | |
| CN104491015A (en) | Traditional Chinese medicine composition for treating allergic conjunctivitis | |
| CN102670772B (en) | Traditional Chinese medicine for treating allergic rhinitis | |
| CN106038877A (en) | Drug compound for treating suppurative otitis media of children and preparation method thereof | |
| CN102349926B (en) | New medical application of combination of paeonol, derivative thereof and paeoniflorin | |
| CN111437309A (en) | Zhuang medicine composition for treating rhinitis and preparation method thereof | |
| CN104324284A (en) | Traditional Chinese medicine extract for treating allergic conjunctivitis and preparation method thereof | |
| CN105561004A (en) | Traditional Chinese medicine composition for preventing and treating chronic nephritis | |
| CN116492383B (en) | External traditional Chinese medicine composition for relieving eye fatigue and preparation method and application thereof | |
| CN107375577A (en) | Treat the Chinese medicine composition and its fumigant preparation method of allergic rhinitis | |
| CN104491013A (en) | Application of traditional Chinese medicine composition to preparation of drug for treating allergic conjunctivitis | |
| CN106377572A (en) | Application of folium cylocaryae paliuri or extract and composition thereof to preparation of health food or medicine for preventing and/or relieving stomach-heat syndrome | |
| WO2023098776A1 (en) | Use of traditional chinese medicine composition in preparation of medication for treating neuritis | |
| CN105327016A (en) | Sticking plaster for treating rhinitis and preparation method for sticking plaster | |
| CN105012751A (en) | Traditional Chinese medicine composition for treating prosopalgia generated after acoustic neuroma operation | |
| CN105435162A (en) | Traditional Chinese medicine composition for treating allergic rhinitis, preparation method and traditional Chinese medicine preparation | |
| CN106581445A (en) | Traditional Chinese medicine prescription for treating diabetic retinopathy | |
| CN106038653A (en) | Pharmaceutical composition for preventing and treating colon cancer | |
| CN106421198A (en) | Novel application of Qiming (fruit of Chinese wolfberry and semen cassiae) traditional Chinese medicinal composition | |
| CN105457002A (en) | Medicine composition for treating respiratory tract infection and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Xiaofeng Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160229 Address after: Yishui Town, Shandong city of Linyi province Yishui 276400 County Xin Hua Road, No. 60 Applicant after: Li Xiaofeng Address before: 1 residential building, No. 443 Changjiang East Road, Huangdao District, Shandong, China, 1708, China, 266520 Applicant before: Chen Da bio tech ltd, Qingdao |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170807 Address after: 250033 No. 2, building 15, North Gate Road, Tianqiao District, Shandong, Ji'nan, 502 Patentee after: Zhang Guosheng Address before: Yishui Town, Shandong city of Linyi province Yishui 276400 County Xin Hua Road, No. 60 Patentee before: Li Xiaofeng |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder |
Address after: 266700 Qingdao, Shandong Province, Cui Jia village, Cui Jia village, Pingdu City, Pingdu City, east side of 603 provincial road Patentee after: Zhang Guosheng Address before: 250033 No. 2, building 15, North Gate Road, Tianqiao District, Shandong, Ji'nan, 502 Patentee before: Zhang Guosheng |
|
| CP02 | Change in the address of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160420 Termination date: 20180704 |